Abstract:Recently, Fiusa and colleagues [1] described that a high angiopoietin (Ang)-2/Ang-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. Although this study failed to detect a statistically significant difference in the levels of vascular endothelial growth factor (VEGF) between both outcome groups, the observed increased Ang-2 concentrations and Ang-2/Ang-1 ratio in the febrile neutropenia subgroup of patients with septic shock address the concept that angiogenic factors could be a promising therapeutic target in sepsis. The imbalance of angiogenic factors and their receptors, including the Ang/Tie2 and VEGF/VEGF receptor pathways, has been shown to predict poor prognosis in sepsis and has been implicated as a contributing factor in multiple organ dysfunction. For these reasons, several strategies targeting Ang/Tie2 and VEGF/VEGF receptor are being explored in preclinical sepsis models; however, most of these agents are unavailable or not applicable in clinical practice. Efforts to develop anticancer agents that target angiogenesis have led to the approval of inhibitors of VEGF and its receptor, specifically bevacizumab. As recently reported in Critical Care, bevacizumab has proven effective in the treatment of sepsis in an animal model [2]. The current study reinforces and extends previous findings that Ang-2 levels are increased in the septic state and have been established as a prognostic biomarker for identification of the patient group with the highest mortality rates. Interestingly, most recently by using Ang-2 antibody treatment, Ziegler and colleagues [3] showed that inhibition of Ang-2 has a significant effect on survival of mice with sepsis. AMG 386 is an investigational peptide-Fc fusion protein that inhibits angiogenesis by preventing the interaction of Ang-1/2 with their receptor, Tie2. The human study demonstrated that intravenous AMG 386 appeared well tolerated, and its safety profile seemed to be distinct from that of VEGF axis inhibitors [4]; it has reached late stages of clinical development. This provides a basis for Ang-2 inhibition as a potential clinical-translational therapeutic target in sepsis. The distinct safety profiles of AMG 386 and the VEGF-axis inhibitors suggest that they could be combined to achieve cooperative action, which may thereby improve clinical efficacy without significant overlapping toxicities. Thus, recent findings indicate that angiogenic factors are potential therapeutic targets in sepsis. However, the safety profiles of these anti-angiogenic agents in septic patients are often complicated by organ dysfunction and may be different from those in cancer patients. Future clinical trials may be needed to evaluate the safety and efficacy of these anti-angiogenic agents in sepsis patients, either alone or in combination.

A Tumor-Targeted Nano-Drug Delivery System Based on Amphiphilic Polyrotaxane-Based Triblock Copolymers

Chitosan Matrices with Three Dimensional Macroporous Structure for Drug Release

Endothelial cell-specific molecule-1/endocan: Diagnostic and prognostic value in patients suffering from severe sepsis and septic shock

Nanoplatforms for Sepsis Management: Rapid Detection/Warning, Pathogen Elimination and Restoring Immune Homeostasis

C-Terminal Alpha-1 Antitrypsin Peptide: A New Sepsis Biomarker with Immunomodulatory Function

Endocan is useful biomarker of survival and severity in sepsis

Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management

Tumor Cell-Derived Exosomal Hybrid Nanosystems Loaded with Rhubarbic Acid and Tanshinone IIA for Sepsis Treatment

Treatment of Severe Sepsis with Nanoparticulate Cell-Free DNA Scavengers

Circulating Neutrophil-Derived Microparticles Associated with the Prognosis of Patients with Sepsis

Angiogenic Factors in Sepsis: Are We Ready for the New Therapeutic Era?

Development of Procathepsin L (pCTS-L)-Inhibiting Lanosterol-Carrying Liposome Nanoparticles to Treat Lethal Sepsis

Identification of procathepsin L (pCTS-L)-neutralizing monoclonal antibodies to treat potentially lethal sepsis

A novel anoikis-related gene signature predicts prognosis in patients with sepsis and reveals immune infiltration

ICAM-1-targeted and Antibacterial Peptide Modified Polymeric Nanoparticles for Specific Combating Sepsis

Therapeutic potential of procathepsin L-inhibiting and progesterone-entrapping dimethyl-β-cyclodextrin nanoparticles in treating experimental sepsis

Serum mitochondrial-encoded NADH dehydrogenase 6 and Annexin A1 as novel biomarkers for mortality prediction in critically ill patients with sepsis

Identification Of Novel Biomarkers For Sepsis Prognosis Via Urinary Proteomic Analysis Using Itraq Labeling And 2d-Lc-Ms/Ms

Novel Biomarkers Associated with Sepsis

Precise engineering of neutrophil membrane coated with polymeric nanoparticles concurrently absorbing of proinflammatory cytokines and endotoxins for management of sepsis

Pathogen Infection-Responsive Nanoplatform Targeting Macrophage Endoplasmic Reticulum for Alleviating Sepsis